November 01, 2016 – Dublin, Ireland and Cambridge, UK – Inflazome, Ltd., a biotech company developing small molecule drugs that stop inflammation driven by our innate immune system, today announced the appointment of two industry leaders with extensive drug discovery and development expertise to its Management Team.
Dr. Angus MacLeod, Vice President, Preclinical R&D - Dr Macleod began his industrial career at Merck in 1984 at the Neuroscience Research Centre in the UK. At Merck, Dr Macleod was responsible for the management of multiple drug discovery programs leading to the nomination of pre-clinical drug candidates, and served on product development teams progressing compounds through to Phase I clinical trials. In 2006, he joined BioFocus, part of the Galapagos group, as head of Medicinal Chemistry and Drug Metabolism and Pharmacokinetics (DMPK), and continued into a broader management role as Executive Director, following acquisition by Charles River Laboratories in 2014. Dr Macleod has extensive experience across a wide range of therapeutic areas and drug target classes. He is co-author of more than 60 papers and an inventor on more than 70 patent applications.
Dr. David Miller, Head of Medicinal Chemistry – Dr Miller’s first industrial position was at Organon Laboratories where he spent over 5 years as a chemistry and project team leader, working on schizophrenia, pain and depression programs. In 2002, Dr Miller moved to a senior role at Amedis Pharmaceuticals, which subsequently merged with Paradigm Therapeutics and the combined company was later acquired by Takeda Pharmaceutical Company. At Takeda, Dr Miller led a team that delivered a compound into the clinic for a challenging Central Nervous System (CNS) target. Upon leaving Takeda he was Associate Director within the Medicinal Chemistry department responsible for analytical chemistry and DMPK. Dr Miller currently has 16 scientific publications and is a named inventor on 9 patents.
Drs MacLeod and Miller will drive Inflazome’s drug discovery and pre-clinical drug development efforts as we create and protect proprietary inflammasome inhibitors to treat inflammatory diseases.
Inflazome is leading the development of orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome, which is now recognised to drive many chronic inflammatory conditions.